Julia Bonavitacola

Top articles in non–small cell lung cancer (NSCLC) include FDA approvals, improved outcomes due to certain treatments, and updated data presented at conferences.

The most-read content for HIV focused on funding cuts to HIV aid and research and satisfaction with telemedicine for HIV care.

The approval of subcutaneous amivantamab allows physicians flexibility in offering treatment for non–small cell lung cancer.

The top ophthalmology content included FDA approvals, FDA complete response letters, and new associations between cataracts and antioxidant index.

Our conference coverage featured updates on clinical trials testing new treatments for NSCLC, bladder cancer, and breast cancer.

The conference focused on how to improve eye care across the country, including new methods of treating dry eye and utilizing new technologies to catch myopia earlier.

Influenza and COVID-19 are seeing an uptick in incidence as the winter months approach, making protecting vulnerable populations a high priority.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

The approval of subcutaneous amivantamab can offer a more accessible means of treatment for patients with non–small cell lung cancer (NSCLC).

Our top conference coverage of the year highlighted findings presented at CROI 2025, ACCC Spring, and EHA, among others.

How strategic partnerships in oncology can enhance patient care by addressing diverse needs through collaboration.

Our top content from the World Conference on Lung Cancer (WCLC) 2025 featured new therapeutic strategies for EGFR+ NSCLC and trial results on amivantamab.

The past year has seen multiple changes in the HIV space that have long-term effects when it comes to ending the epidemic.

Top content from CROI 2025 focused on COVID-19 and HIV, including the safety of a vaccine in people taking antiretroviral therapy.

Artificial intelligence and lung cancer highlighted the top conference coverage from the Association of Cancer Care Centers Annual Meeting in Washington, DC.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

The oral medication could be used in gonorrhea that is resistant to antibiotics according to a new phase 3 clinical trial.

Both health care plans brought forward by Republican and Democratic senators, respectively, did not garner enough support from across the aisle.

The incidence of age-related macular degeneration could be linked to handgrip strength according to an analysis of the UK Biobank.

Although a cure is likely still a ways off, continuing to pursue long-acting injectable treatments and PrEP is key to reducing cases of HIV.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Experts met in Park City, Utah, on October 7, 2025, to discuss how new technologies can help address chronic kidney disease.

Patients with stage I to IIIA NSCLC had lower 2- and 4-year mortality in states that expanded Medicaid coverage.

As open enrollment continues, 77% of surveyed Americans were happy with their options for 2026 health care coverage, although cost concerns surfaced.

Speakers at the Institute for Value-Based Medicine event held September 18, 2025, in Nyack, New York, spoke about methods of managing cardio-renal-metabolic disease.

New research shows that those with dry eye need more than 20 blinks per minute to maintain their tear film.

Avoiding losses of coverage due to administrative barriers can be done with a focus on making some of the processes automatic.

The combination of olomorasib and pembrolizumab to treat KRAS G12C-mutant advanced NSCLC showed promising antitumor activity.

Lenacapavir and cabotegravir are among the most important advancements in HIV prevention and treatment within the past 10 years.

The uninsured rates may skyrocket when Medicaid work requirements go into effect and if the Affordable Care Act (ACA) subsidies are not extended.